Durabolin IM Injection 25 mg/ml
Durabolin IM Injection 25 mg/ml Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Durabolin IM Injection 25 mg/ml |
| Generic | Nandrolone Phenylpropionate |
| Weight | 25 mg/ml |
| Type | IM Injection |
| Therapeutic Class | Anabolic steroid (Androgens), Hormone in bone formation by stimulation |
| Manufacturer | Nuvista Pharma Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Durabolin IM Injection 25 mg/ml is indicated- As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance For the palliative treatment of selected cases of disseminated mammary carcinoma in women Osteoporosis.Dosage
Durabolin IM Injection 25 mg/ml dosage
As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: Recommended dose is 25-50 mg every week.For the palliative treatment of selected cases of disseminated mammary carcinoma in women: Recommended dose is 50 mg every week.Osteoporosis: Recommended dose is 50 mg every week.For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet. Durabolin IM Injection 25 mg/mlshould be administered by deep intramuscular injection.Side Effects
High dosages, prolonged treatment and/or too frequent administration may cause: Virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. Amenorrhoea. Inhibition of spermatogenesis. Premature epiphyseal closure. Fluid retention.Precaution
If signs of virilisation develop, discontinuation of the treatment should be considered, Preferably in consultation with the patient.It is recommended to monitor patients with any of the following conditions: latent or overt cardiac failure, renal dysfunction, hypertension or migraine (or a history of these conditions), since anabolic steroids may occasioally induce fluid retention: incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases of breast carcinoma. In these patients hypercalcaemia may develop both spontaneously and as a result of anabolic steroid therapy. The later can be indicative of a positive tumour response to the hormonal treatment. Nevertheless, the hypercalcaemia should first be treated appropriately and after restoration of normal calcium levels hormone therapy can be resumed; liver dysfunction. The use of anabolic steroids to enhance athletic ability may carry severe risks to the user's health and should be discouraged.Interaction
Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other antidiabetic medicines in diabetics.Pregnancy & Breastfeeding use
This medicine is contraindicated during pregnancy because of possible masculinization of the foetus. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the infant or a possible influence on milk production.Contraindication
Contraindicated in Pregnancy, Known or suspected carcinoma of the prostate or breast in the male.Acute Overdose
The acute toxicity of Durabolin IM Injection 25 mg/ml in animals is very low. There are no reports of acute overdosage with Durabolin IM Injection 25 mg/ml in the humanStorage Condition
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.Innovators Monograph
You find simplified version here Durabolin IM Injection 25 mg/ml
